Cargando…

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

INTRODUCTION: On the basis of reductions in diabetic kidney disease (DKD) progression and major adverse cardiovascular events observed in the landmark CREDENCE trial, canagliflozin 100 mg received an extension to its EU marketing authorisation in July 2020 to include the treatment of DKD in people w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willis, Michael, Nilsson, Andreas, Kellerborg, Klas, Ball, Philip, Roe, Rupert, Traina, Shana, Beale, Rebecca, Newell, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843731/ https://www.ncbi.nlm.nih.gov/pubmed/33263893 http://dx.doi.org/10.1007/s13300-020-00968-x

Ejemplares similares

Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
por: Scilletta, Sabrina, et al.
Publicado: (2023)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
por: Chiu, Nicholas, et al.
Publicado: (2022)

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials
por: Flack, John M., et al.
Publicado: (2023)

The role of lncRNAs in regulation of DKD and diabetes-related cancer
por: Cheng, Yawei, et al.
Publicado: (2022)

Detection of DKD stage 1 and treatment are essential
por: Futrakul, Narisa, et al.
Publicado: (2018)

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD
por: de Sá, João Roberto, et al.
Publicado: (2022)

2DKD: a toolkit for content-based local image search
por: DeVille, Julian S., et al.
Publicado: (2020)

The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters
por: Al-Rubeaan, Khalid, et al.
Publicado: (2018)

Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
por: Bae, Jaehyun, et al.
Publicado: (2021)

Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives
por: Tanase, Daniela Maria, et al.
Publicado: (2022)

Role of Sphingolipid Signaling in Glomerular Diseases: Focus on DKD and FSGS
por: Mitrofanova, Alla, et al.
Publicado: (2020)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Effects of liraglutide on extraglycemic inflammatory markers and renal hemodynamic parameters in diabetic kidney disease (DKD)
por: Song, Wenjuan, et al.
Publicado: (2023)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Virtual Patient Simulation in DKD: Successful Strategy for Improving Recognition and Management
por: Larkin, Amy, et al.
Publicado: (2021)

Network Pharmacology-Based Prediction of Mechanism of Shenzhuo Formula for Application to DKD
por: Wang, Xinmiao, et al.
Publicado: (2021)

Lessons learned from two randomized controlled trials: CITIES and STOP-DKD
por: Zullig, Leah L., et al.
Publicado: (2020)

ODP223 Metabolic efficacy of Very Low Carbohydrate Diet in DKD patients
por: Zainordin, Nur Aisyah, et al.
Publicado: (2022)

Both sexes develop DKD in the CD1 uninephrectomized streptozotocin mouse model
por: Trink, Jackie, et al.
Publicado: (2023)

A qualitative study documenting unmet needs in the management of diabetic kidney disease (DKD) in the primary care setting
por: Datar, Manasi, et al.
Publicado: (2021)

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
por: Filippatos, Gerasimos, et al.
Publicado: (2021)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
por: Rossing, Peter, et al.
Publicado: (2021)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study
por: Rossing, Peter, et al.
Publicado: (2022)

The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome–metabolome combined validation in a mouse model
por: Shang, Jin, et al.
Publicado: (2022)

Identification of a New RNA and Protein Integrated Biomarker Panel Associated with Kidney Function Impairment in DKD: Translational Implications
por: Scamporrino, Alessandra, et al.
Publicado: (2023)

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
por: van den Berg, Paul, et al.
Publicado: (2021)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice
por: Wu, Jiajia, et al.
Publicado: (2023)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher, Haroon, et al.
Publicado: (2019)

Race, Income, and Medical Care Spending Patterns in High-Risk Primary Care Patients: Results From the STOP-DKD (Simultaneous Risk Factor Control Using Telehealth to Slow Progression of Diabetic Kidney Disease) Study
por: Machen, Leah, et al.
Publicado: (2021)

Mechanistic Study of Schisandra chinensis Fruit Mixture Based on Network Pharmacology, Molecular Docking and Experimental Validation to Improve the Inflammatory Response of DKD Through AGEs/RAGE Signaling Pathway
por: Li, Hongdian, et al.
Publicado: (2023)

Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials
por: Cai, Jennifer, et al.
Publicado: (2018)

Emerging treatments in type 2 diabetes: focus on canagliflozin
por: Rosiak, Marek, et al.
Publicado: (2014)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
por: Erondu, Ngozi, et al.
Publicado: (2015)

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2015)

Canagliflozin: a novel treatment option for type 2 diabetes
por: Dietrich, Eric, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q57umpsvm8d7mujuhhh26n7fov